Please assess the completion status of the following clinical trial:

Trial Title: Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with AML with the FLT3-ITD mutation who have undergone allogeneic HSCT~* Peripheral blood chimerism studies showing \>/= 70% of all cells are of donor origin~* Adequate hematologic and hepatic function~* ECOG performance status 0-2~* Able to swallow whole pills~Exclusion Criteria:~* Evidence of relapsed/recurrent/residual disease as assessed by bone marrow aspirate and biopsy performed between days 30-60 after HSCT~* Active acute graft vs host disease requiring an equivalent dose of \> 0.5 mg/kg/day of prednisone or equivalent or those patients which necessitated the addition of another agent for the treatment of GVHD beyond corticosteroids~* Ongoing uncontrolled infection~* Cardiac disease: congestive heart failure \> class II NYHA, unstable angina or new onset angina (began within the last 3 months) or myocardial infarction within the past 6 months~* Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy~* Uncontrolled hypertension~* Known HIV infection or chronic hepatitis B or C~* Thrombotic or embolic events such as cerebrovascular accident including transient ischemic attacks within the past 6 months~* Pulmonary hemorrhage/bleeding event \> CTCAE v 4.0 Grade 2 within 4 weeks of starting study drug~* Any other hemorrhage/bleeding event \> CTCAE v. 4.0 Grade 3 within 4 weeks of starting study drug~* Serious non-healing wound, non-healing ulcer, or bone fracture~* Evidence or history of bleeding diathesis or coagulopathy~* Major surgery or significant traumatic injury within 4 weeks of starting study drug~* Use of St. John's Wort or rifampin (rifampicin)~* Known or suspected allergy to sorafenib~* Pregnant or breast-feeding~* Receiving any other investigational agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Post-SCT Sorafenib (Type: EXPERIMENTAL): Sorafenib will be given as maintenance therapy after allo HCT to patients with FLT3-ITD AML.

Based on this trial design, predict the completion outcome and termination type (if applicable).